Evidence map›Paper›PMID 34222078›Full record

ArticleJournal of diabetes and metabolic disorders2021

Nephroprotective effect of Vanillic acid in STZ-induced diabetic rats.

Savita Kumari, Anjoo Kamboj, Manish Wanjari, Anil Kumar Sharma

Open access · greenAbstract read
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Nephroprotective Effect ofInternational journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  19. Article
  20. Protective effects of vanillic acid on letrozole-induced polycystic ovarian syndrome: A comprehensive study in female wistar rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Savita KumariDepartment of Pharmacology, IKG-PTU (Punjab Technical University), Jalandhar, Kapurthala, 144603 Punjab India.
Anjoo KambojDepartment of Pharmacy, Chandigarh College of Pharmacy, Landran, Mohali, 140307 Punjab India.ORCID 0000-0002-9846-4019
Manish WanjariDepartment of Pharmacology, Regional Ayurveda Research Institute for Drug Development Aamkho, Gwalior, 474009 M.P India.
Anil Kumar SharmaDepartment of Pharmacognosy, R&D, AIMIL Pharmaceuticals (India) Ltd, New Delhi, 110008 India.
Chandigarh University · INDepartment of Pharmaceuticals · INMinistry of AYUSH · INPunjab Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the protective effect of vanillic acid (VA) in streptozotocin (STZ)-induced diabetic nephropathy (DN) in rats.

methodsExperimental diabetes mellitus in rats was induced by intraperitoneally administration of single dose of STZ (55 mg/kg). The animals were divided into 5 groups viz., normal control, diabetic control, glimepiride (0.5 mg/kg, orally) and VA treatment (50 and 100 mg/kg, orally) groups. The treatment was started after the confirmation of hyperglycemia (> 250 mg/dl) and continued for 6 weeks. Serum glucose level, and body weight were measured weekly. At the end of study, HbA1c in whole blood, insulin, lipid profile, urea, creatinine and albumin in serum. Creatinine and albumin were measured in urine along with creatinine clearance. In addition, kidney weight and histopathology were assessed.

resultsTreatment with VA markedly attenuated STZ-induced body weight loss and hyperglycemia, along with improved lipid profile and HbA1c, without significant alteration of serum insulin levels. It also decreased urea, creatinine and increased albumin in serum. Moreover, VA, significantly reduced urine volume, urinary albumin along with marked improvement in creatinine clearance. Further, the VA treatment significantly reverse the raised levels of oxidative stress markers, pro-inflammatory and fibrotic markers viz. TNF-α, IL-1β, IL-6, TGF-β1 and NFκB activity in kidney tissue. These effects are associated with amelioration of histopathological alterations compared to diabetic control rats. While glimepiride produced similar antihyperglycemic effect but the effect on albuminuria, oxidative stress markers and cytokine levels were less significant as compared to VA (100 mg/kg).

conclusionsIn conclusion, VA exhibited nephroprotective effect through amelioration of kidney dysfunction and damage in diabetic rats. The observed nephroprotective effect of VA may be ascribed to inhibition of hyperglycemia induced oxido-inflammatory stress and necroptosis of renal tissue possibly due to its antihyperglycemic, antioxidant and anti-inflammatory actions.

Indexed as

AlbuminuriaAntioxidantsGimepirideInsulinNecroptosisVanillic acid

Identifiers

PMID34222078
PMCPMC8212202
OpenAlexW3147908754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.